Typhoid vi polysaccharide vaccine - Biologic Drug Details

Summary for typhoid vi polysaccharide vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for typhoid vi polysaccharide vaccine

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Salmonella Typhi Vaccine
Chemical Structure	Polysaccharides, Bacterial Vaccines, Inactivated Vaccines, Typhoid

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for typhoid vi polysaccharide vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for typhoid vi polysaccharide vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for typhoid vi polysaccharide vaccine Derived from Patent Text Search

No patents found based on company disclosures

Market dynamics and financial trajectory for the typhoid Vi polysaccharide vaccine

Last updated: February 16, 2026

The typhoid Vi polysaccharide vaccine (Typbar-TCV, Typbar, Typhim Vi) is a key product in typhoid fever prevention, with a market driven by global health priorities, expanding vaccination programs, and emerging regional demand. The vaccine's positioning impacts its market growth and revenue potential.

---

How has the demand for typhoid Vi polysaccharide vaccines evolved?

Demand hinges on endemicity, immunization policies, and outbreak threats. The World Health Organization (WHO) recommends typhoid vaccination in high-breg regions, with recent campaigns increasingly including Vi polysaccharide vaccines.

Between 2014 and 2022, global vaccination campaigns expanded particularly in South Asia and Sub-Saharan Africa. The expanded use of conjugate vaccines, such as Typbar-TCV, which offers longer-lasting immunity, influences market growth by displacing older polysaccharide formulations.

The global typhoid vaccine market was valued at approximately $370 million in 2022. Growth is projected at a compound annual growth rate (CAGR) of 8% over 2023-2028, driven by increasing vaccination coverage and new market entrants.

What regulatory and policy influences affect market growth?

Regulatory approvals and government policies significantly impact market trajectory. WHO prequalification of Typbar-TCV in 2018 increased procurement and distribution channels. Countries such as India, Nigeria, and Indonesia have integrated typhoid vaccines into routine immunization schedules, aligning with WHO recommendations.

The Gavi Alliance’s support for typhoid vaccination in eligible countries accelerates demand, providing funding for vaccine procurement and distribution. In 2021, Gavi committed over $250 million to typhoid immunization programs in endemic nations.

Policy shifts favoring conjugate vaccines over polysaccharide types, owing to their improved efficacy in children under two, are compelling manufacturers to develop and promote these formulations, potentially reducing the market share of traditional Vi polysaccharide vaccines but also expanding overall vaccine utilization.

What are the key market players, and how do their strategies influence the financial outlook?

主要疫苗制造商包括¼

• Takeda Pharmaceutical (producer of Typbar-TCV): Focuses on expanding access via Gavi-funded initiatives, increasing manufacturing capacity, and pursuing new approvals in emerging markets.
• Sanofi (producer of Typhim Vi): Offers traditional Vi polysaccharide vaccines, primarily targeting adult populations and regions with existing immunization infrastructure.
• Biological E Limited: Developing indigenous typhoid conjugate vaccines to capture regional markets, especially in India.

Takeda dominates the market with an estimated 60% share, benefiting from WHO prequalification and its strong presence in low- and middle-income countries.

How do manufacturing and innovation trends influence financial prospects?

Manufacturers worldwide are investing in conjugate vaccine development, which replaces polysaccharide vaccines for comprehensive immunization coverage. Typbar-TCV’s efficacy in young children and single-dose regimen give it a competitive advantage.

Production costs for conjugate vaccines are higher, with estimates around $1.50–$3.00 per dose. The pricing models for governments and NGOs often range from $0.50 to $2.50 per dose, depending on subsidy levels and procurement volume.

The shift to conjugate vaccines indicates potential market contraction for traditional polysaccharide vaccines, but overall market size is expected to grow due to increased demand in endemic regions and expanded immunization programs.

What are the key challenges and risks?

Risks include:

• Pricing and reimbursement issues: Variability in government procurement budgets constrains sales.
• Vaccine hesitancy: Can slow adoption, especially in regions with less public health infrastructure.
• Competition from emerging conjugate vaccines: Expanded options may pressure pricing and margins for existing polysaccharide vaccines.
• Manufacturing capacity constraints: Supply chain bottlenecks and production costs can limit growth.

---

Financial outlook and projections

Year	Market Size (USD million)	Growth Rate	Key Drivers
2023	390	8%	Expanded vaccination campaigns
2024	421	8%	WHO prequalification influence
2025	455	8%	Gavi-supported procurement
2026	493	8%	Adoption of conjugate vaccines
2027	534	8%	New country immunization policies

Market expansion hinges on increased access in endemic regions, successful conjugate vaccine rollout, and sustained global health funding.

---

Key Takeaways

• Demand is driven primarily by immunization programs in endemic regions and WHO recommendations.
• Gavi support, evolving policies favoring conjugate vaccines, and regional manufacturing influence market growth.
• The traditional Vi polysaccharide vaccines face displacement as conjugate vaccines gain prominence but benefit from expanding overall vaccine needs.
• Market size is expected to grow at a CAGR of approximately 8% through 2028, driven by increased access and regulatory approvals.
• Manufacturing capacity, pricing, and regional health policies present ongoing risks and opportunities.

---

FAQs

1. What factors will influence future demand for typhoid Vi polysaccharide vaccines?

Demand will depend on immunization policy adoption, funding from global health initiatives like Gavi, and the transition to conjugate vaccines, which may replace polysaccharide formulations in routine schedules.

2. How does WHO prequalification impact vaccine sales?

Prequalification facilitates procurement by UN agencies and Gavi-supported countries, expanding market reach and boosting sales.

3. Will traditional Vi polysaccharide vaccines disappear?

They will likely decline in favor of conjugate vaccines for pediatric use but remain relevant in adult immunization and regions with limited access to newer formulations.

4. What regions present the largest market opportunities?

South Asia, Sub-Saharan Africa, and Southeast Asia have the highest endemicity, with expanding immunization programs opening growth avenues.

5. How do manufacturing costs influence vaccine pricing?

Higher development and production costs for conjugate vaccines lead to higher prices, but subsidies and bulk purchasing reduce end-user costs, impacting market margins.

---

References

[1] WHO. Typhoid vaccines: WHO position paper – 2018.
[2] Gavi. Typhoid immunization programs overview.
[3] Market research reports on global typhoid vaccine market (2022).